At the recently held Retina World Congress 2026 meeting, Texas Retina’s Dallas Director of Clinical Research Ashkan M. Abbey, MD, presented on the evolving clinical trial landscape for sustained drug delivery in retinal disease.
Dr. Abbey’s talk focused on EYP-1901 (vorolanib intravitreal insert) and the growing body of data supporting durable treatment strategies for both wet age-related macular degeneration (AMD) and diabetic macular edema (DME). He highlighted updates from the DAVIO 2, VERONA, LUGANO/LUCIA, and COMO/CAPRI clinical trials. Texas Retina has been involved with studies for EYP-1901 since its inception.
About EYP-1901
EYP-1901 is an intravitreal insert designed to provide sustained release of the tyrosine kinase inhibitor (TKI) vorolanib, which works intracellularly to inhibit pan-VEGF receptor signaling. It also inhibits PDGFR and blocks inflammatory IL-6 signaling through the JAK pathway.
The goal of EYP-1901 is to provide long-term visual and anatomic stability in wet AMD and DME with fewer injections over time compared with standard anti-VEGF medication dosing. The current phase 3 clinical trials are evaluating dosing approximately every 6 months.
Aiming to Reduce Treatment Burden for Patients
At the meeting, Dr. Abbey discussed the potential for sustained-release therapies to reduce treatment burden while maintaining strong visual and anatomic outcomes, as well as the emerging role of multi-target tyrosine kinase inhibition.
“It was especially exciting to review how ongoing phase 3 studies may help shape the future of long-term retinal disease management,” shared Dr. Abbey. “Thanks to the organizers, investigators, study coordinators, and especially the patients participating in these important trials, the pace of innovation in retina continues to accelerate, and it is an extremely exciting time for our field.”
Click HERE to watch a video about Dr. Abbey’s Retina World Congress 2026 presentation on EYP-1901.
You can access a full list of Texas Retina’s currently enrolling clinical trials HERE, including EYP-1901-303 (COMO) for DME.